Safety of haloperidol and penfluridol in pregnancy: A multicenter, prospective, controlled study

Journal of Clinical Psychiatry

Volumn 66, Issue 3, 2005, Pages 317-322

  Diav Citrin, Orna ^a   Shechtman, Svetlana ^a   Ornoy, Shani ^a   Arnon, Judy ^a   Schaefer, Christof ^b   Garbis, Hanneke ^c   Clementi, Maurizio ^d   Ornoy, Asher ^a,e  

^a MINISTRY OF HEALTH   (Israel)

^b Pharmakovigilanz /Beratungszentr E   (Germany)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d Servizio di Informazione Teratologica   (Italy)

^e HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYROPHENONE DERIVATIVE; HALOPERIDOL; PENFLURIDOL;

ADULT; ARTICLE; BIRTH WEIGHT; CANCER RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; DRUG FORMULATION; DRUG SAFETY; FEEDING DISORDER; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HEART ARRHYTHMIA; HIGH RISK PREGNANCY; HUMAN; IRRITABILITY; LIMB DEFECT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE HYPOTONIA; NERVOUSNESS; OUTCOMES RESEARCH; PREGNANCY; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PSYCHOSIS; RESTLESSNESS; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; TERATOGENICITY;

EID: 16444363257     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0307     Document Type: Article

References (26)

1. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376
2. Migdalof BH, Grindel JM, Heykants JJ, et al. Penfluridol: a neuroleptic drug designed for long duration of action. Drug Metab Rev 1979;9:281-299
3. Bertelli A, Polani PE, Spector R, et al. Effect of a neuroleptic, haloperidol, on the gestation and prenatal development of rodents: results of 3 groups of experiments [in French]. Arzneimittelforschung 1968;18:1420-1424
4. Hamada Y, Hashiguchi M. Teratogenicity of butyrophenone derivatives in mice [abstract]. Teratology 1978;18:148
5. Gill TS, Guram MS, Geber WF. Haloperidol teratogenicity in the fetal hamster. Dev Pharmacol Ther 1982;4:1-5
6. Vichi F. Neuroleptic drugs in experimental teratogenesis. In: Bertelli A, Donati L, eds. Teratology Proceedings. Amsterdam: Excerpta Medica; 1969:87-101
7. Vichi F, Pierleoni P. Effetti letali e teratogeni dell haloperidol in embroni di topo. [Lethal and teratogenic effects of haloperidol in mouse embryos,] Riv Ital Stomatol 1970;25:585-596
8. Jurand A, Martin LVH. Teratogenic potential of two neuroleptic drugs, haloperidol and dextromoramide, tested on mouse embryos. Teratology 1990;42:45-54
9. Szabo KT, Brent RL. Species differences in experimental teratogenesis by tranquillising agents [letter]. Lancet 1974;1:565
10. Sullivan-Jones P, Hansen DK, Sheehan DM, et al. The effect of teratogens on maternal corticosterone levels and cleft incidence in A/J mice. J Craniofac Genet Dev Biol 1992;12:183-189
11. Dieulangard P, Coignet J, Vidal JC. Sur un cas d'ectro-phocomélie, peut-être d'origine médicamenteuse. Bull Fed Gynecol Obstet Lang Fr 1966;18:85-87
12. Kopelman AE, McCullar FW, Heggeness L. Limb malformations following maternal use of haloperidol. JAMA 1975;231:62-64
13. van Waes A, van de Velde E. Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. J Clin Pharmacol 1969;9:224-227
14. Hanson JW, Oakley GP. Haloperidol and limb deformity [letter]. JAMA 1975;231:26
15. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002:642
16. Clementi M, Di Gianantonio E, Omoy A. Teratology information services in Europe and their contribution to the prevention of congenital anomalies. Community Genet 2002;5:8-12
17. Steer RA, Scholl TO, Hediger ML, et al. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992;45:1093-1099
18. Orr ST, Miller CA. Maternal depressive symptoms and the risk of poor pregnancy outcome: review of the literature and preliminary findings. Epidemiol Rev 1995;17:165-171
19. Howard LM, Goss C, Leese M, et al. Medical outcome of pregnancy in women with psychotic disorders and their infants in the first year after birth. Br J Psychiatry 2003;182:63-67
20. Marcelis M, van Os J, Sham P, et al. Obstetric complications and familial morbid risk of psychiatric disorders. Am J Med Genet 1998;81:29-36
21. Sacker A, Done DJ, Crow TJ. Obstetric complications in children born to parents with schizophrenia: a meta-analysis of case-control studies. Psychol Med 1996;26:279-287
22. Bennedsen BE, Mortensen PB, Olesen AV, et al. Preterm birth and intra-uterine growth retardation among children of women with schizophrenia. Br J Psychiatry 1999;175:239-245
23. Williams R, Ali SF, Scalzo F, et al. Prenatal haloperidol exposure: effects on brain weights and caudate neurotransmitter levels in rats. Brain Res Bull 1992;29:449-458
24. Holson RR, Webb PJ, Grafton TF, et al. Prenatal neuroleptic exposure and growth stunting in the rat: an in vivo and in vitro examination of sensitive periods and possible mechanisms. Teratology 1994;50:125-136
25. Gillberg C. "Floppy infant syndrome" and maternal diazepam [letter]. Lancet 1977;2:244
26. Rementeria JL, Bhatt K. Withdrawal symptoms in neonates from intrauterine exposure to diazepam. J Pediatr 1977;90:123-126